Dry Eye Syndrome
CF101 has successfully completed a Phase II study in dry eye syndrome, meeting its primary endpoints and demonstrating the drug`s ability to improve signs of ocular surface inflammation in moderate-to-severe dry eye syndrome patients. CF101 was well tolerated and exhibited an excellent safety profile with no serious adverse events. The study results were published in ‘Ophthalmology’, which is one of the leading journals in the ophthalmology field 10.
Measurements of intraocular pressure (IOP) in the Phase II dry eye syndrome trial, monitored for safety assessment in patients with normal baseline values, showed a statistically significant reduction in IOP in the tested subjects. This observation indicated that CF101 may also have potential as a treatment for glaucoma and led to our current Phase II clinical trial in glaucoma.
Recent animal data emerging from studies carried out in collaboration with Dr. Rachel Caspi at the National Eye Institute (Betesda, US), have demonstrated that CF101 is effective in suppressing ocular inflammation in experimental model of uveitis, indicating that the anti-inflammatory activity of CF101 can be beneficial in the treatment of uveitis, a chronic, idiopathic, sight-threatening disease. The results of this study were published in the ’International Journal of Molecular Medicine’ 11.